Bayesian inference of genetic pleiotropy identifies drug targets and repurposable medicines for human complex diseases

Noah Lorincz-Comi[1,2], Feixiong Cheng[1,2,3,*]

[1]Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

[2]Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

[3]Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA

*Correspondence to Feixiong Cheng, Ph.D.

Lerner Research Institute, Cleveland Clinic

Tel: +1-216-444-7654; Fax: +1-216-636-0009

Email: chengf@ccf.org

Keywords: Polygenicity, pleiotropy, druggable genes, complex disease, genome-wide association study, gene association testing

Summary

Complex diseases share heritable components which can be leveraged to identify drug targets with low side effect or high repurposing potential, but current methods cannot efficiently make these inferences at scale using public data. We introduce a Bayesian model to estimate the polygenic structure of a trait using GWAS summary data (BPACT). Across 32 complex traits, we estimated that 69.5 to 97.5% of disease-associated druggable genes are shared between multiple traits. We observed that targeting *KIT* for ALS prevention may increase triglyceride levels, but that targeting *TBK1* and *SCN11B* may be safer because of they were not pleiotropic. We additionally found 21 candidate repurposable drug targets for Alzheimer's disease (AD) (e.g., *PLEKHA1*, *PPIB*) and 5 for ALS (e.g., *GAK*, *DGKQ*) based on the directionality of their pleiotropy. Our results demonstrate that modeling shared genetic architecture across traits can uncover safer therapeutic targets and highlight opportunities for drug repurposing in complex diseases.

Keywords: polygenic, pleiotropy, complex disease, druggable genes, drug repurposing

Motivation

We intend to identify genes which are associated with multiple complex traits such that their side effect or therapeutic repurposing potential is large. We present a Bayesian method leveraging gene-based association test statistics that can be used to jointly characterize shared polygenicity between complex trait pairs and make these inferences.

Introduction

Understanding the extent to which the heritability of a complex trait is conferred by few or many genes, i.e., its 'polygenicity', is a first step in understanding its genetic etiology [1]. Similarly, quantifying the degree to which two distinct traits have heritability which is contributed by shared and non-shared genes helps researchers better contextualize phenotypic similarities between them [2] [3]. This information can even be used to guide drug targeting decisions [4], namely how the targeting of one gene with a drug may reduce the risk and/or symptoms of a target disease while simultaneously inducing side effects because the gene is also associated with other traits [5] [6] [7]. On the other hand, genes associated with known disease risk factors can also be candidate drug targets [8]. A notable example of this is the targeting of low-density lipoprotein by inhibiting *PCSK9* expression to reduce coronary artery disease risk [9] [10]. The first step in inferring shared gene associations between multiple traits is generally to separately test each gene for association with each trait and to make a joint inference for the pair.

Inference of a shared gene association with multiple traits can be accomplished using standard hypothesis testing with gene-based test statistics from genome-wide association studies (GWAS) [11]. Then, a joint inference can be made using the intersection-union test at the SNP or gene level [12]. However, this process is highly sensitive to GWAS sample size, inherently limits the available interpretation only to nonzero disease association, and cannot be used to reliably characterize polygenicity genome-wide. Researchers also cannot make inferences about non-association at the

gene level using hypothesis testing, which is required for identifying genes whose drugs

have limited off-target potential. Hypothesis testing also relies almost entirely on the

statistical power available to detect disease-associated SNPs in GWAS, which is

primarily driven by the polygenic structure itself and GWAS sample size [13] [14]. For

example, counts of rejected independent gene-based null hypotheses estimate the

number of associated genes that exist for a single trait, but this estimate is biased in

finite GWAS samples. Similarly, inference of no association between a gene and trait

can only be validly made from a non-rejected null hypothesis when GWAS sample size

is infinitely large.

These limitations make polygenic inference using hypothesis testing alone potentially

unreliable and unflexible [15]. Instead, directly modelling the polygenic structure of

complex traits and leveraging statistical methods which can supply a model-based

posterior inference each trait in a pair may provide more consistent estimates of shared

polygenicity and make a wider range of inferences available to researchers. However,

currently available methods do not completely account for linkage disequilibrium

correlation between their measured units (i.e., SNPs, genes) and can only provide

polygenic inferences at the genome-wide or SNP levels [16] [17] [18], which in many

applications are of at least secondary interest to the gene level.

We present a general statistical model which computes the posterior probability that

each gene contributes to additive heritability using gene-based test statistics and an

empirically derived model of polygenicity. This approach is leveraged to estimate the

total number of genes which are putatively associated with each of 32 complex traits

and the proportions of genes contributing shared and non-shared additive heritability

across them. Our results suggest large variability across traits in the estimated number

of associated genes, from less than 20 to over 900, and that the vast majority of disease

associated genes are associated with multiple traits. These results highlight the role of

prioritizing trait-exclusive risk genes as putative drug target candidates with less off-

target effects. We show as an example that targeting the *KIT* gene for ALS prevention

may reduce ALS risk while simultaneously increasing triglyceride levels, which could

harm overall health. On the other hand, genes with evidence of pleiotropy across

multiple traits can be leveraged if their associations are in the direction of risk, and we

provide two demonstrative examples of this scenario for AD with *PLEKHA1* and ALS

with *GAK*.

Results

Overview

We presented a Bayesian method to infer the polygenic architectures of complex traits

(BPACT) under a model for SNP heritability of the tth complex trait using gene-based

association test statistics from the set of all tested genes genome-wide $\{T_k^t\}$. In this

model, we estimate the proportion of causal genes $1 - \delta$ and the outcome variance-

scaled SNP heritability τ_t and calculate the posterior probability that the kth gene is

associated with risk of the tth trait (PRP_{kt}) as

$$\mathrm{PRP}_{kt} = \int_{\delta_t \in \Delta_t} \int_{\tau_t \in \mathrm{T}_t} f(T_k^t | \delta_t, \tau_t) p_{\delta_t}(\delta_t | T_k^t) p_{\tau_t}(\tau_t | T_k^t) d\delta_t d\tau_t, \tag{1}$$

which integrates over the estimation error of (δ_t, τ_t) using the distributions p_{δ_t} and p_{τ_t}

which are developed empirically. Integration over the spaces of the causal model

parameters (τ_t, δ_t) allows us to account for misspecification of the model by its

parameters. We infer the shared polygenic architecture for two traits t and t' using

$\{\mathrm{PRP}_{kt}\}$ and $\{\mathrm{PRP}_{kt'}\}$ while correcting for participant overlap between the GWAS from

which $\{T_k^t\}$ and $\{T_k^{t'}\}$ were calculated (*cf.* **Methods**). Inferences of genes with potentially

low side effect potential are those for which

$$123 \qquad \mathrm{PRP}_{kt} \times \left[1 - \prod_{\{s:s \neq t\}} (1 - \mathrm{PRP}_{ks}) \right] \qquad (2)$$

124   approaches 1. Inferences of potentially repurposable genes for the tth trait are those for

125   which

$$126 \qquad \mathrm{PRP}_{kt} \times \sum_{\{s:s \neq t\}} \mathrm{PRP}_{ks} r_g(t, s; k) d_s \qquad (3)$$

is high, where $r_g(t, s; k) d_s$ is the genetic correlation between traits t and s in the local

region of the kth gene, i.e., $d_s \in \{1, -1\}$. We use the risk-directed genetic correlation

$r_g(t, s; k) d_s$ to infer that the therapeutic targeting of the kth gene for the tth trait may be

accomplished by targeting the sth trait. Although the PRP_{kt} quantity is a probability

derived from a causal model, we limit our epidemiological inferences in specific disease

contexts just to disease association and not causality, which could be better assessed

using experimental approaches. We account for GWAS sample overlap between trait

pairs in all analyses using a modified simulation extrapolation (SIMEX) approach [19]

(*cf.* **Methods**). Results presented in the **Supplement** show that this removes any bias

in estimated shared polygenicity between trait pairs, which for all trait pairs was small to

begin with.

Estimating polygenicity among 32 human complex diseases

We estimated the number of disease-associated genes (DAGs) for 32 complex traits

and display the counts in **Figure 1a**. These results suggest that traits such as body

mass index (BMI), high-/low-density lipoprotein (HDL/LDL), schizophrenia (SCZ),

intelligence (INT), and diastolic, systolic, and pulse pressure (DBP, SBP, PP) may have

more than 500 DAGs, while other traits such as Alzheimer's disease (AD) or

amyotrophic lateral sclerosis (ALS) may only have only 100-300. These counts are also

highly correlated with the number of independent Bonferroni- and FDR-significant genes

scaled by the square root of GWAS sample size, denoted respectively as sBonf and

sFDR, which in the **Supplement** are shown to be proportional to the true number of

disease associated genes. Hence, linear correlation of our estimated numbers of DAGs

with sBonf (Pearson r=0.92) and sFDR (r=0.98) implies at least linear correlation

between our estimates and the true numbers of true disease-associated genes.

Independence between genes that were significant in hypothesis testing with gene-

based association test statistics was inferred using the clumping procedure in [20]

based on shared LD between gene-specific SNP sets. Our estimated counts of disease

associated genes are also not correlated with GWAS sample size (Pearson r=0.02, P-

value=0.900) or is square root (Pearson r=0.07, P-value=0.691) across the 32 traits,

suggesting that they are not heavily influenced by statistical power in GWAS, the

primary source of which is sample size.

Figure 1b shows an example of the relationship between gene-level posterior risk

probabilities (PRPs) using our method and gene-based association test P-values from

the GenT method [20] for AD on chromosome 1. These results show that genes with the

smallest P-values are most likely to be assigned a large PRP, such as *CR1* and

B4GALT3. Though detecting gene-trait associations is not the primary goal of BPACT,

genes which fail to meet the level of genome-wide significance in gene-based testing

can still be assigned large PRPs under the BPACT model. One example was *SH2D2A*,

which had PRP of 0.97 for AD but gene-based test P-value of 1.1E-5, above the

Bonferroni significance level of 3.9E-6 (*cf.* **Methods**). *SH2D2A* is associated with

neuronal signaling via synapse formation [21] and has previously been shown to be

overexpressed in AD cases vs controls in immune cells [22], suggesting it may indeed

be associated with AD risk.

Figure 1c displays the gene- and trait-specific posterior risk probabilities (PRPs)

summed within each chromosome. These results suggest that the genes associated

with the 32 traits are not uniformly distributed across the 22 chromosomes, but that

chromosome 17 may contain the largest number of DAGs, despite it only containing the

fifth largest number of tested genes (see **Supplementary Figure S9**). These counts are

contributed from associated genes from all traits, and no small subset of traits

dominates the chromosome-specific counts for any chromosome. We show in **Figure**

1d an example of how gene-level posterior risk probabilities can be used to provide an

inference of shared association between coronary artery disease (CAD) and LDL, a

known CAD risk factor [23]. These results highlight two lead loci on chromosome 7

which are likely shared between CAD and LDL, indexed by *DDX56* (7p13) and *DUS4L*

(7q22.3), due to their posterior shared risk probabilities (S-PRPs) near 1.

Estimating shared polygenicity among complex diseases

On average, an estimated 2.4 to 29.7% (mean=16.8%) of trait-associated genes are not

shared with any other traits (**Figure 2a**). For example, of the estimated 120 genes which

are inferred to associate with risk of major depression, only 14 (SE=0.89; 11.7%) are not

associated with at least one other trait. Similarly, of the 58 genes inferred to associate

with chronic kidney disease (CKD), only 13 (SE=0.81; 22.4%) are estimated to be

specific only to CKD. We also estimate the total number of genes across the genome

which are not associated with any of the 32 traits as 8,312 (SE=40.25), implying that

approximately 50.9% (SE=2.5E-3) of the 16,324 genes tested for association with each

of the 32 traits we studied may contribute to the SNP heritability of at least one of them

(*cf.* **Methods**). **Figure 2b** shows the matrix of cosine similarity values [24] between all

trait pairs, which is the ratio of shared disease associated gene counts to the geometric

means of total disease associated gene counts for each trait pair. Larger cosine

similarity values indicate greater degrees of associated gene sharing between trait

pairs. The row/column ordering of traits in **Figure 2b** is determined by hierarchical

clustering, and these results suggest that genetic similarity may be used to

approximately group phenotypically similar traits into distinct clusters including a

psychiatric/behavioral cluster, a metabolic/cardiovascular cluster, and an age-related/

autoimmune cluster. These clusters show greater evidence of associated gene sharing

within them than between, and some traits such as stroke and chronic kidney disease

show little evidence of gene sharing with any other trait, potentially explained by their

low SNP heritability (**Supplementary Figure S4**). Together, these results suggest that

cosine similarity indices applied to our estimates of shared association at the gene-level

can be used to identify phenotypically similar traits, supporting our use of shared PRPs

to identify shared genetic architecture between traits.

A case study of polygenic sharing between traits is presented in **Figure 2c** for Lewy

body dementia (LBD) using both the cosine and Jaccard [25] indices. These results

show that the average LBD-associated gene is most likely to be shared with highly

polygenic traits such as TG, SCZ, and BMI. But, after considering the estimated sizes of

disease associated gene sets of LBD and the other traits, LBD is most genetically

similar to Parkinson's disease (PD), Alzheimer's disease (AD), and a multivariate index

of healthy aging (mvAGING; [26]). This is supported by their shared phenotype of age-

related neurodegeneration. For example, there is an estimated 0.19 probability that a

randomly selected LBD-associated gene is associated with PD risk, and an estimated

0.32 probability that a randomly selected LBD risk gene is associated with AD risk. We

show in the **Supplement** that cosine index values for AD with the other 31 traits are

mildly linearly correlated with their estimated genetic correlations (Pearson r=0.31)

using LD score regression [13]. But, for some traits such as MDD, LDL, and EDU, there

is evidence of a nonzero proportion of shared associated genes but no evidence of a

nonzero global genetic correlation between them. Across all 496 trait pairs, the linear

correlation between absolute genetic correlations and cosine index values was 0.22

(P=8.0E-7).

Two case studies of gene sharing between AD and LBD are presented in **Figure 2d** for

two loci which are respectively indexed by *KCTD13* (16p11.2) and *SLC8B1* (12q24.13).

KCTD13 had a posterior probability of being shared by AD and LBD of 1.00 and is

associated with brain morphology [27] and known to affect short-term memory by

regulating synaptic activity in the hippocampus [28]. The inhibition of *SLC8B1* has also

been shown to reduce cognitive performance and memory in mice [29] and its

expression may protect against neuronal cell death [30]. Together, this supporting

evidence suggests associations of *KCTD13* and *SLC8B1* with impaired memory, a

hallmark symptom of both AD and LBD.

Discovery of non-pleiotropic drug target candidates in ALS

We next provide a motivating example of how shared PRPs can be used to identify

candidate drug targets for ALS with limited potential for off-target effects on other traits

(*cf.* Equation 8). **Figure 3a** displays PRPs for ALS and for ALS but not any of the other

31 traits using the set of 3,369 genes with drug targets (i.e., 'druggable genes'; *cf.*

Methods). These results suggest that *TBK1* and *SCNN1B* have the largest PRPs (0.87

and 0.89, respectively) of associating with ALS but none of the other 31 phenotypes.

This suggests they may have lower off-target potential compared to other drug targets

with respect to side effects on any of the other 31 traits. As a counterexample, the *KIT*

gene is associated with ALS, triglycerides (TG), high-density lipoprotein (HDL), Bipolar

I/II disorder (BIP), and body mass index (BMI). **Figure 3b** shows the SNP-level

associations between ALS, TG, and gene expression in the thyroid from GTEx v8 [31] in

the *KIT* locus. These results suggest the presence of nonzero associations between

SNPs in this locus and ALS, TG, and *KIT* expression. There is also evidence of a

negative local genetic correlation between ALS and TG and between ALS and thyroid

gene expression, and a positive local genetic correlation between TG and thyroid gene

expression. Mendelian Randomization (MR) using all FDR-significant thyroid eQTLs as

instruments and observed eQTL and ALS Z-statistics as in [32] suggested a negative

causal effect of *KIT* expression on ALS risk (Estimate= –0.12; P=1.8E-8). These results

suggest that while decreased *KIT* expression in the thyroid may reduce ALS risk, this

may simultaneously be associated with increased TG levels, potentially harmful to

overall health.

The sharing of disease association between *KIT* with ALS and TG, and the

corresponding non-sharing of the *SCNN1B* and *TBK1* genes with ALS only, is

demonstrated in **Figure 3c**. We note that non-sharing of association between ALS and

non-ALS traits is not a requirement for a putatively safer ALS drug target, but that the

set of genes with low non-ALS trait associations may contain genes with less complex

biological pathways of effect and hence better candidates as therapeutics with limited

side effect potential. **Figure 3d** displays estimated counts of shared and non-shared

disease associated genes that have drug-target interactions for all traits, made by

directly summing PRPs for these genes. These results suggest that for some traits such

as multiple sclerosis (MS), PD, and LBD, currently available drug targets are likely to

associate with at least one other trait. These results also suggest that approximately 14

druggable genes are candidate ALS targets with limited evidence of conferring off-target

effects by modifying any of the other 31 traits. Of these 14, the *TBK1* and *SCNN1B*

genes have the strongest evidence of ALS association and limited non-ALS association.

We provide trait-specific PRPs and pairwise trait-shared PRPs for all 3,369 druggable

genes for all traits in the **Supplemental Data**.

Discovery of non-pleiotropic drug target candidates in Alzheimer's disease (AD)

We also leveraged estimated shared polygenicity between AD and each of the other 31

traits to identify candidate drug targets which have limited evidence of side effect

potential. Some examples of these genes include *EARS2*, *EPHA1*, *ITGA2B*, *MME*, and

MS4A2, each of which have a PRP with AD greater than 0.9, and no PRP with any other

trait greater than 0.9 (**Supplementary Figure S10**). The *MS4A2* gene is a member of

the *MS4A* gene cluster (11q12.1) which is known to play a critical role in autoimmune

activation [33] [34] and even moderate effects of the well-known AD risk gene *TREM2*

[35] [36]. On the other hand, many well-known druggable AD risk genes have evidence

of pleiotropic association with other traits (**Supplementary Figure S10**). These genes

include *ACE*, *APOC2*, *APOE*, *BIN1*, and *CLU*. As examples, *CLU* had PRP with AD of

0.99 and with SCZ of 1.00; *APOC2* had PRP with AD of 1.00 and PRPs with TG, LDL,

HDL, and CAD each of 1.00. *CLU* may simultaneously confer risk of AD and SCZ

because of its role in and response to autoimmunity and inflammation, which is

dysregulated in both AD and SCZ cases vs controls [37] [38] [39]. *APOC2* is known to

be involved in the metabolism of lipoprotein [40], and so has been implicated in

hypertriglyceridemia risk [41], suggesting that its conferral of AD risk may be mediated

by lipidemia.

Repurposable drug candidates using BPACT

We leveraged the shared association of a gene with multiple disease trait(s) to identify

candidate drug targets that may have a therapeutic effect on multiple diseases

simultaneously. We refer to these genes as repurposable drug candidates since they

may already have some demonstrated evidence of treating one condition but have so

far not been extensively evaluated for the treatment of another. For these genes, a

genetic correlation between the target disease and other traits in the direction of risk

(e.g., positive correlation for T2D and LDL cholesterol, negative correlation for T2D and

intelligence), suggests that targeting them with a drug may have therapeutic effects on

each trait simultaneously. We identified these genes as those with large PRPs for

multiple traits with which the index trait was locally genetically correlated in the direction

of risk with all other traits on average (*cf.* Equation 3) and present these quantities in

Figure 4a. These results suggest that traits such as SCZ, CAD, and T2D may have the

largest number of repurposable candidates, which is expected since these traits have

evidence of being highly polygenic (**Figure 1a**), and that traits such as lupus and MS

may not have any known associated genes that are not associated with at least one

other trait.

As a demonstrative example, we show in **Figure 4b** that *PLEKHA1* is associated with

BMI, intelligence (INT), and Type 2 diabetes (T2D), and that the directions of their local

genetic correlations with AD suggests that targeting *PLEKHA1* may have

therapeutic/preventative effects on all traits including AD. In this locus, six SNPs

(rs10788284, rs6585827, rs2421016, rs7097701, rs10510110, rs2280141) are

associated with both AD and each of BMI, INT, and T2D at level P<5E-5 in intersection-

union tests (IUTs). The rs10510110 SNP of *PLEKHA1* was associated with AD

(FDR=3.2E-3) and gene expression (GTEx v8; [31]) in visceral adipose (FDR=3.6E-7),

brain cortex (FDR=3.4E-2), and thyroid tissue (FDR=1.8E-9) (**Figure 4c**). Citric acid

(CA) is a nutraceutical agent interacting with *PLEKHA1* (DrugBank, DB04272; [42]) that

is traditionally recognized for its association with BMI, lipid cholesterol, and glucose

metabolism [43] [44]). There is additional evidence suggesting that CA can modulate

oxidative stress in the brain by reducing inflammation and lipid peroxidation [45],

potentially via its role in fatty acid metabolism [46] and/or its inhibition of the

acetylcholinesterase (AChE) enzyme [47]. AChE inhibitors have demonstrated efficacy

in treating AD symptoms [48], and one hypothesized mechanism is via the deformation

of amyloid-beta tangles [49] [50].

Similarly to AD and *PLEKHA1*, two SNPs in the *GAK* locus (rs3775121, rs873785) were

associated with HDL, PD, and TG (P<5E-5), and their local genetic correlations with

ALS were each in the direction of risk for all traits. The rs3775121 SNP was associated

with ALS (FDR=5.3E-3) and gene expression (GTEx v8; Lionsdale et al., 2018) in aortic

(FDR=1.4E-3), blood (FDR=2.8E-4), and colon tissue (FDR=2.2E-3) (**Figure 4c**).

Fostamatinib is a drug which primarily inhibits spleen-associated kinase (*SYK*), but can

also inhibit many additional kinases including cyclin-G-associated kinase (*GAK*)

(DrugBank, DB12010; [42]). Fostamatinib was originally developed to treat immune

conditions such including autoimmune hemolytic anemia, thrombocytopenia, and

immunoglobulin A nephropathy [51], though bioinformatic analyses using MR and

molecular docking support fostamatinib as a potential therapeutic target for ALS and PD

[52] [53] [54]. Fostamatinib may have evidence as a candidate ALS target because *SYK*

and *GAK* can cause inflammation-associated cell death and cognitive impairment [55]

[56] [57] [58], a hallmark symptom of ALS.

In summary, BPACT identified genes which may be drug repurposing candidates for

complex traits including ALS and AD. These genes had evidence of association with

multiple traits each in the direction of risk such that targeting them with a drug could

lead to therapeutic effects for all associated traits. We demonstrated this phenomenon

using the AD-associated *PLEKHA1* gene and ALS-associated *GAK* gene. These genes

interact with available compounds – citric acid with *PLEKHA1* and fostamatinib with

GAK – and the literature provides supporting evidence that these compounds associate

with AD and ALS pathology. Future functional and experiment studies may provide

greater insight into the degree to which these compounds may simultaneously confer

protective effects against AD/ALS and other traits.

Discussion

We present BPACT, which can be used to estimate the number of genes which

contribute to the SNP heritability of a single trait or multiple traits. We used BPACT to

show that more than half of the genome has evidence of explaining SNP heritability in at

least one of the 32 traits we studied. Results from analyses of shared heritability

highlighted druggable genes that have evidence of reducing disease risk at the potential

cost of side effects, and we demonstrated this phenomenon using *KIT* for ALS as an

example. Our results also showed how BPACT can be used to identify genes which are

candidate therapeutic targets for multiple traits simultaneously, and we demonstrated

this used AD and ALS as examples.

We began by showing that there is substantial variability in the estimated number of

disease associated genes (DAGs) across the 32 traits. BPACT was also able to identify

a highly polygenic group of traits which included BMI, DBP, SBP, pulse pressure (PP),

LDL, HDL, TG, INT, BIP, and SCZ. Estimates of polygenicity correlated almost perfectly

with the number of GWAS significant genes adjusted for sample size, which we showed

in the **Supplement** to be proportional to the true number of associated genes for a

given trait. This concordance provides supporting evidence that our estimator of the

number of disease associated genes is at least proportional to the true number of

disease associated genes for the trait. Since this quantity is adjusted for GWAS sample

size, it may not be strongly related to GWAS statistical power. We then showed that the

estimated number of disease associated genes (DAGs) across all 32 traits is not

uniformly distributed across chromosomes after adjusting for the number of genes they

contain (**Supplement Figure S9**), and that chromosome 17 had the largest estimated

number of genes which were putatively associated with any trait.

We next showed that most genes which explained nonzero heritability in a trait were

shared with at least one other trait. For example, we estimated that 24.9% of genes

associated with ischemic stroke risk and only 2.5% of genes associated with the index

of aging (mvAGING) were not associated with any other trait we tested. We then

showed that cosine and Jaccard indices applied to total and shared DAG counts can be

used to measure their shared polygenicity. These quantities were reported in the

Supplement to moderately positively correlate with estimated global absolute genetic

correlations. But, for some trait pairs, we find evidence of substantial sharing but

estimated genetic correlations very close to 0. These results provide empirical evidence

that shared polygenicity is a weaker form of genetic similarity than genetic correlation,

and that global null estimates of genetic correlation do not imply genetic independence

between traits.

The evidence also suggested that most trait-associated genes with known drug

interactions were shared across multiple traits, and we showed an example of the *KIT*

gene associated with ALS, BIP, TG, HDL, and BMI. Expression of *KIT* in the thyroid was

negatively associated with ALS risk but positively associated with TG levels, suggesting

that targeting of *KIT* with an inhibitor may reduce ALS risk but simultaneously elevate

TG levels, a potentially harmful side effect. We presented the *TBK1* and *SCNN1B*

genes as examples of alternative druggable candidates, each of which were associated

with ALS but had no evidence of association with any of the other 31 traits. *TBK1* can

mediate activation of the NF-κB transcription factor which regulates innate and

adaptative immunity processes [59] [60] [61], and targeting of *TBK1* with fostamatinib

has been demonstrated to reduce ALS risk in vitro [53]. *SCNN1B* has been shown to

suppress the MAPK signaling pathway [62] which is dysregulated in ALS patients [63]

[64].

Our results also showed that leveraging gene pleiotropy across multiple traits may

nominate repurposable drug targets, and two examples included *PLEKHA1* with AD and

GAK with ALS. These targets can be viewed as potentially therapeutic for an index trait

because of modification to one or more of its risk factors, or simultaneous therapeutic

effects on multiple traits via independent biological pathways. *PLEKHA1* is expressed

across many tissues including the brain, heart, and adipose tissue (GTEx v8; [31]), and

contains the pleckstrin homology protein folding domain which is associated with the

binding of phosphorylated lipids onto inositol rings [65]. Knockout of *GAK* has been

shown to disrupt the homeostasis of lysosomes during autophagy [57], and like

PLEKHA1 it is expressed across many tissues including the brain, heart, and adipose

tissue [31]. The pleiotropic effects of these genes on multiple phenotypically distinct

traits may be explained by their broad expression patterns across multiple tissues. We

showed that the proportion of genes for which shared associations with other traits can

be detected is generally large, emphasizing that the richest source of candidate drug

targets for a complex disease may be provided by the set of pleiotropic genes.

Our study is strengthened by the generality of the underlying statistical model and the

wide range of inferences which can be made once it is fitted. The model is also

advantageous because it accounts for its own parameter misspecification by integrating

over the prior parameter space. Gene-level posterior risk probabilities can be used to

infer trait-specific association, trait-shared association, and trait non-association in the

context of the BPACT statistical model. We also provide expressions for the effect of

GWAS sample overlap on gene-based test statistic correlations and the working number

of independent gene-based association tests genome-wide (*cf.* **Methods**). These

quantities have henceforth been absent in the literature and have respectively

precluded direct comparison of gene-based test statistics from multiple GWAS cohorts

and well-calibrated control of Type I error rates in genome-wide testing. We proposed a

new approach to address the challenge of correlated gene-based test statistics (*cf.*

Methods) during inference, which is based on the well-studied SIMEX approach [19].

We show in the **Supplement** that this procedure removes any extant bias in estimated

counts of shared associated genes between trait pairs due to GWAS sample overlap.

We also present a new model-fitting approach for correlated gene-based test statistics

based on composite posterior densities which are iteratively evaluated over randomly

selected and weakly correlated gene sets (*cf.* **Methods**). This approach uses the

principles of imputation to make its inference, and without it our approach could lead to

inflated estimates of disease associated gene counts because of shared LD between

gene-specific SNP sets. Finally, **Supplementary Table S1** shows that our method is

computationally efficient, spending approximately 15 minutes to run on an Intel® Xeon®

Gold 6148 CPU 2.40GHz machine.

BPACT has the following limitations. Estimates of DAG counts and their shared

proportions adjust for GWAS sample size, but do assume accurate phenotyping, correct

specification of the gene-based test statistic null distributions, and that genes only have

non-interacting effects on the trait. Violations of any of these assumptions may bias the

estimated DAG counts via mis-specified model priors and likelihood functions. Our

model intends to account for misspecification of model parameters, but does assume a

correctly specified model structure of additive SNP heritability. If the structure and/or

parameters of these models are inappropriate for some traits, or for some loci for some

traits, it may cause the model to return a gene-level PRP which is far from the true value

of the latent binary indicator of association. This could have downstream negative

consequences on estimated shared and non-shared DAG counts for traits and their

pairs. Our model also assumes that within each block of correlated gene-based test

statistics, only a single disease associated gene is present. Future extensions of the

BPACT method may attempt to relax this assumption. Finally, an inherent limitation of

using gene-based test statistics to make the aforementioned inferences is that any

nuance at the SNP level may not be completely captured at the gene level. However,

this aggregation across SNPs in a gene-specific set is what makes gene-based test

statistics statistically powerful [20].

In addition to inferences related to drug target identification and polygenicity

evaluations, future researchers may also use BPACT and its results to evaluate the

degree to which increases in GWAS sample sizes are likely to detect additional genes

explaining meaningful amounts of heritability. For example, we estimate that 133 genes

associate with AD, and a recent AD GWAS has detected 82 independent loci [66]. This

suggests that increasing AD GWAS sample size may be likely to produce new

meaningful insights into the genetic etiology of AD. However, for traits such as BMI, for

which we estimate that approximately 943 associated genes may exist, the currently

reported ~1,000 BMI-associated loci [67] may cover most of the entire associated gene

set and so further investment in continually larger BMI GWAS sample sizes may not

return the same value which it requires. Finally, the integration of quantitative trait loci

(QTL) data into the BPACT model may help it to nominate drug targets with supporting

transcriptomic, proteomic, epigenomic, and/or metabolomic evidence that may have

greater therapeutic potential than those identified just from GWAS summary statistics.

Methods

SNP-level model

Our gene-level model is built from a SNP-level random effect model for a single trait. Let

β_j^k represent the marginal association between the jth SNP of the kth gene and a trait,

$r_{jj'}$ the LD correlation between SNPs j and j' corresponding to the gene, ℓ_j the LD

score of the jth SNP (i.e., sum of squared LD correlations with surrounding SNPs in a

window of fixed size; [13], a_j the corresponding minor allele frequency, N the GWAS

sample size, and ϕ_h^2 the average SNP heritability explained by each of $\ddot{M}$ causal SNPs

genome-wide. Let G_{ij} represent the dosage of risk alleles of the jth SNP from the ith

person in the GWAS and $\sigma_j^2 := \mathrm{E}(G_{ij}^2) = 2\alpha_j(1 + \alpha_j)$. We use the following SNP-level

models:

499
$$\beta_j^k \sim N(0, \phi_h^2 \ell_j), \qquad \mathrm{Cov}(\beta_j^k, \beta_{j'}^k) = 0$$

500
$$u_j := (\hat{\beta}_j^k - \beta_j^k) \xrightarrow{D} N\left(0, \frac{\phi_Y^2}{N\sigma_j^2}\right), \qquad \mathrm{Corr}(u_j, u_{j'}) = r_{jj'}$$

$$\hat{\beta}_j^{\mathrm{k}} = \beta_j^k + u_j,$$

$$\sqrt{N}\sigma_j\phi_Y^{-1}\hat{\beta}_j^k \xrightarrow{D} N\big(0, \tau\ell_j N\sigma_j^2 + 1\big), \qquad \tau := \phi_h^2\phi_Y^{-2}$$

where ϕ_Y^2 is the scaled conditional variance of the phenotype given the genotype for the

jth SNP. For binary phenotypes, ϕ_Y^2 acts also as a scaling factor which is proportional to

the trait prevalence that in effect indicates a transformation from the observed binary

scale to the underlying liability scale [68]. It follows from the definition of τ that $\tau :=$

$h^2\ddot{M}^{-1}\phi_Y^{-2}$ is likely to be very small in practice when $\ddot{M}$ is large and/or ϕ_Y^{-2} is large and

SNP heritability h^2 is small. Let $\widehat{\boldsymbol{\beta}}_k = \big(\hat{\beta}_j^k\big)$ be the vector of estimated SNP effect sizes

for all SNPs in the set corresponding to the kth gene. The correlation matrix of $\widehat{\boldsymbol{\beta}}_k$ is

approximately the LD matrix $\mathbf{R}_k$ under this model [69].

Gene-level model

The SNP-level model is used to construct a gene-level model for the distribution of

gene-based test statistics $\{T_k\}$. Let the kth of M genes across the genome be tested

using the statistic T_k calculated from m_k SNPs in the set $\mathcal{S}_k$, i.e.

$$T_k = \sum_{j \in \mathcal{S}_k} N\hat{\sigma}_j^2 \hat{\phi}_Y^{-2}\big(\hat{\beta}_j^k\big)^2 \qquad (1)$$

[20] showed that under $H_{0k}\colon \mathrm{E}(T_k) = m_k$, $T_k \sim \Gamma(\alpha_{0k}, \xi_{0k})$ approximately and under

$H_{1k}\colon \mathrm{E}(T_k) > m_k$, $T_k \sim \Gamma(\alpha_{1k}, \xi_{1k})$ approximately, using the shape-rate parameterizations

of each Gamma distribution. Let $\mathbf{z}_k = \big(\sqrt{N}\hat{\sigma}_j\hat{\phi}_Y^{-1}\hat{\beta}_j^k\big)$, $\mathbf{L}_k = \mathrm{diag}(\ell_j)$ and $\mathbf{D}_k = \mathrm{diag}(\sigma_j^2)$

for $j \in \mathcal{S}_k$, and $\mathbf{H}_k := \mathbf{D}_k^{1/2}\mathbf{L}_k\mathbf{D}_k^{1/2}$ such that $\mathrm{Cov}(\mathbf{z}_k|H_{1k}) = N\tau\mathbf{H}_k + \mathbf{R}_k$ and $\mathrm{Cov}(\mathbf{z}_k|H_{0k}) =$

$\mathbf{R}_k$. It is shown in the **Supplement** that

522
$$\xi_{1k} = \frac{m_k + N\tau \sum_{j=1}^{m_k} \sigma_j^2 \ell_j}{2\text{tr}(\mathbf{R}_k \mathbf{R}_k) + 2(N\tau)^2 \sum_{j=1}^{m_k} \sigma_j^4 \ell_j^2 + 4N\tau \sum_{j=1}^{m_k} \sigma_j^2 \ell_j}$$
(2)

523   and

524
$$\alpha_{1k} = \left(m_k + N\tau \sum_{j=1}^{m_k} \sigma_j^2 \ell_j \right) \xi_{1k}.$$
(3)

525   It follows immediately that $\xi_{0k} = m_k \text{tr}(2\mathbf{R}_k \mathbf{R}_k)^{-1}$ and $\alpha_{0k} = m_k \xi_{0k}$. We use these

526   quantities to model the data-generating process of the statistic T_k as

527
$$T_k \sim \delta\Gamma(\alpha_{0k}, \xi_{0k}) + (1 - \delta)\Gamma(\alpha_{1k}, \xi_{1k})$$
(4)

528   where $1 - \delta$ is the marginal probability that gene k is causally associated with the

529   phenotype under this model. This mixture can alternatively be expressed as

530
$$T_k = (1 - I_k)\Gamma(\alpha_{0k}, \xi_{0k}) + I_k \Gamma(\alpha_{1k}, \xi_{1k})$$
(5)

where $P(I_k = 1) = 1 - \delta$, $P(I_k = 0) = \delta$, and I_k is a latent indicator of causality for the

kth gene.

Estimating the number of disease associated genes and their shared counts

We presented a <u>B</u>ayesian method to infer the <u>p</u>olygenic <u>a</u>rchitectures of <u>c</u>omplex <u>t</u>raits

(BPACT) and the sharing of architectures between pairs of them. In this model, we

calculate the posterior probability that the kth gene is associated with risk of the tth trait

(PRP_{kt}) as

539
$$\text{PRP}_{kt} = \int_{\delta_t \in \Delta_t} \int_{\tau_t \in T_t} P(I_k^t | T_k^t, \delta^t, \tau^t) p_{\delta_t}(\delta_t | T_k^t) p_{\tau_t}(\tau_t | T_k^t) d\delta_t d\tau_t$$
(6)

540
$$= E(I_k^t | T_k^t)$$

541 where $p_{\delta_0^t}(\delta^t|T_k^t)$ and $p_{\tau_0^t}(\tau^t|T_k^t)$ are posterior distributions of δ^t and τ^t, respectively,

542 which are assumed conditionally independent given T_k^t, and

$$P(I_k^t|T_k^t, \delta^t, \tau^t) = \frac{f_1^t(T_k^t; \tau^t)(1 - \delta^t)}{f_1^t(T_k^t; \tau^t)(1 - \delta^t) + f_0^t(T_k^t; 0)\delta^t} \; , \tag{7}$$

where $f_1^t(\,\cdot\,; v_1^t)$ and $f_0^t(\,\cdot\,; v_0^t)$ respectively are the non-null and null distributions of T_k^t

parameterized by $\tau^t \leftarrow v_1^t$ and $\tau^t \leftarrow v_0^t$. The quantity PRP_{kt} is interpreted as the posterior

probability that gene k causes trait t given the statistic T_k^t, δ^t, τ^t, and their distributions

$p_{\delta_0^t}$ and $p_{\tau_0^t}$ in the spaces Δ_t and T_t, which can be interpreted as adjustments for the

estimation error of $(\hat{\delta}_k^t, \hat{\tau}_k^t)$. We estimate the posterior distributions $p_{\delta_0^t}(\delta^t|T_k^t)$ and

$p_{\tau_0^t}(\tau^t|T_k^t)$ by sampling from their distributions computationally using the Metropolis-

Hastings algorithm described in the **Supplement** and thereafter model them with Beta

and Trapezoidal distributions, respectively.

We infer the shared polygenic architecture for two traits t and t' using $\{\mathrm{PRP}_{kt}\}$ and

$\{\mathrm{PRP}_{kt'}\}$ while correcting for participant overlap between the GWAS from which $\{T_k^t\}$ and

$\{T_k^{t'}\}$ were calculated (see the next subsection). Inferences of genes with potentially low

off-target effects are those for which

$$\mathrm{PRP}_{kt} \times \prod_{\{s:s\neq t\}} (1 - \mathrm{PRP}_{ks}) \tag{8}$$

558 is high, and inferences of potentially repurposable genes for the tth trait are made for

559 those for which

$$\mathrm{PRP}_{kt} \times \sum_{\{s:s\neq t\}} \mathrm{PRP}_{ks} r_g(t, s; k) d_s \tag{9}$$

is high, where $r_g(t,s;k)d_s$ is the re-signed genetic correlation between traits t and s in

the local region of the kth gene, i.e., $d_s \in \{1,-1\}$. We use the risk-directed genetic

correlation $r_g(t,s;k)d_s$ to infer that the therapeutic targeting of the kth gene for the tth

trait may be accomplished by targeting the sth trait. Although PRP_{kt} is a conditional

probability under a model representing statistical causality, we describe our practical

epidemiological inferences in specific disease contexts just to disease risk association

and not causality, which could be better assessed using experimental approaches.

We estimate the total number of disease associated genes for trait t using S randomly

selected, mutually weakly correlated, and chromosome-specific sets of genes, denoted

as $\mathcal{C}_r(s)$ for chromosome $r = 1, ..., R$ at the sth iteration, and pooling results across the

S replicates and R chromosomes to produce the estimate:

573
$$c(t) = \frac{1}{S}\sum_{s=1}^{S}\sum_{r=1}^{R}\sum_{k \in \mathcal{C}_r(s)} \mathrm{PRP}_{kt} \, . \tag{10}$$

574   We can estimate the number of shared associated genes between traits t and t' as

575
$$c(t,t') = \frac{1}{S}\sum_{s=1}^{S}\sum_{r=1}^{R}\sum_{k \in \mathcal{C}_r(s)} \mathrm{PRP}_{kt}\mathrm{PRP}_{kt'} \, , \tag{11}$$

which assumes independence between T_k^t and $T_k^{t'}$ for all k. Independent sets of genes

from each chromosome at the sth iteration are constructed such that the correlations

between all pairs of gene-based test statistics in the set $\mathcal{C}_r(s)$ are below a fixed level,

which in practice we set as $\sqrt{0.5}$. Since many of such sets may exist, we first define

approximately independent blocks of genes using the $\sqrt{0.5}$ threshold for $\mathrm{Corr}(T_k, T_{k'})$

and the correlation block-sorting method of [70] in the bigsnpr R package. For each

block and chromosome at each iteration, we randomly select one gene and add it to the

set $C_r(s)$. Across the 16,324 genes which were tested for association with all 32 traits in

our real data analysis, 8,148 independent blocks of gene-based test statistics were

present. The inferences of total, $c(t)$, and shared, $c(t, t')$, association are therefore

based on composite posterior densities fitted multiple times for S iterations, over which

the results are pooled to produce the final estimates. We calculate standard errors for

estimated quantities using the imputation principles of [71] across the S iterations. We

estimated the number of genes which are associated with any trait by first subtracting

from 1 the product of all trait-specific posterior risk probabilities and summing them

across all independent genes. When then divided this quantity by the estimated number

of independent gene blocks, 8,148, and multiplied it by 20K.

Effect of sample overlap on estimated shared gene counts

In the previous subsection, we introduced $c(t, t')$ which assumed T_k^t was uncorrelated

with $T_k^{t'}$ for the kth gene and tth, t'th phenotypes. We show in this subsection that

overlapping subjects between the GWAS in which T_k^t and $T_k^{t'}$ were calculated can

induce nonzero spurious correlation between T_k^t and $T_k^{t'}$, and how we can correct for it.

For generality and to illustrate the motivation for considering independent blocks of

genes in our polygenicity estimation, we show the correlation between gene-based test

statistics in the case of different genes and for two traits from different GWAS cohorts

which may contain overlapping subjects. Let $\mathbf{R}_{kk'}$ represent the matrix of LD

correlations between SNPs in the gene-specific sets for genes k and k', $\mathbf{Y}_{tt'} = (v_{tt'})$,

and $v_{tt'} \approx N_{tt'}(N_t N_{t'})^{-1/2} \text{Corr}(t, t')$ [72], which represents the approximate correlation

between T_h^t and $T_h^{t'}$ for any gene index h using GWAS of continuous traits t and t' of

sizes N_t and $N_{t'}$ containing $N_{tt'}$ overlapping subjects. For binary traits, $v_{tt'}$ will have a

slightly different expression but the general principle is the same [72]. It follows that

608
$$\tilde{\mathbf{z}}(k, k'; t, t') := \begin{pmatrix} \mathbf{z}_k^t \\ \mathbf{z}_{k'}^{t'} \end{pmatrix} \sim N \left(\mathbf{0}, \mathbf{G}_{kk'}^{tt'} := \begin{bmatrix} \mathbf{R}_{kk} & v_{tt'}\mathbf{R}_{kk'}^\top \\ v_{tt'}\mathbf{R}_{kk'} & \mathbf{R}_{k'k'} \end{bmatrix} \right) \tag{12}$$

609 under H_{0k}^t and $H_{0k}^{t'}$ and that $\|\tilde{\mathbf{z}}(k, k'; t, t')\|_2^2 = T_k^t + T_{k'}^{t'}$. It remains to find

610 $\mathrm{Var}\left(T_k^t + T_{k'}^{t'} | H_{0k}^t, H_{0k}^{t'} \right)$, which is equal to $\mathrm{Var}(T_k^t | H_{0k}^t) + \mathrm{Var}\left(T_k^{t'} | H_{0k'}^{t'} \right) +$

611 $2\mathrm{Cov}\left(T_k^t, T_k^{t'} | H_{0k}^t, H_{0k}^{t'} \right)$ and where

612
$$\mathrm{Var}\left(T_k^t + T_{k'}^{t'} | H_{0k}^t, H_{0k}^{t'} \right) = 2\mathrm{tr}\left(\mathbf{G}_{kk'}^{tt'} \mathbf{G}_{kk'}^{tt'} \right) \tag{13}$$

613
$$= 2\mathrm{tr}(\mathbf{R}_k \mathbf{R}_k) + 2\mathrm{tr}(\mathbf{R}_{k'} \mathbf{R}_{k'}) + 4v_{tt'}^2 \mathrm{tr}\left(\mathbf{R}_{kk'}^\top \mathbf{R}_{kk'} \right),$$

614 since $\mathrm{Var}(T_k^t | H_{0k}^t) = 2\mathrm{tr}(\mathbf{R}_k \mathbf{R}_k)$ and $\mathrm{Var}\left(T_{k'}^{t'} | H_{0k'}^{t'} \right) = 2\mathrm{tr}(\mathbf{R}_{k'} \mathbf{R}_{k'})$, implying that

615
$$4v_{tt'}^2 \mathrm{tr}\left(\mathbf{R}_{kk'}^\top \mathbf{R}_{kk'} \right) = 2\sqrt{2\mathrm{tr}(\mathbf{R}_{kk} \mathbf{R}_{kk})2\mathrm{tr}(\mathbf{R}_{k'k'} \mathbf{R}_{k'k'})} \mathrm{Corr}(T_{kt}, T_{k't'}) \tag{14}$$

616
$$\Rightarrow \mathrm{Corr}(T_{kt}, T_{k't'}) = v_{tt'}^2 \frac{\mathrm{tr}\left(\mathbf{R}_{kk'}^\top \mathbf{R}_{kk'} \right)}{\sqrt{\mathrm{tr}(\mathbf{R}_{kk} \mathbf{R}_{kk})\mathrm{tr}(\mathbf{R}_{k'k'} \mathbf{R}_{k'k'})}}.$$

This quantity is strictly positive and states that the correlation between gene-based test

statistics from different genes and for different traits from separate GWAS is proportional

to the product of shared LD between gene-specific SNP sets, the proportion of shared

GWAS subjects, and the phenotypic correlation between the traits. The quantity $v_{tt'}^2$ has

as its maximum the square of phenotypic correlation $\mathrm{Corr}(t, t')$ in a single GWAS

cohort. This shows that any pair of gene-based tests statistics, and by extension PRP_{kt}

and $\mathrm{PRP}_{kt'}$, are not generally independent if there are overlapping GWAS subjects and

SNPs in LD between the SNP sets. This motivates correction of $c(t, t')$ for nonzero

correlation between PRP_{kt} and $\text{PRP}_{kt'}$.

To perform this correction in practice, researchers can either (i) de-correlate SNP-level

Z-statistics for each trait pair using the method of [72] before applying gene-based

association testing and subsequent polygenicity evaluations to each trait, or (ii) apply

our post-hoc correction to the estimated number of shared disease associated genes

using the principles of simulation extrapolation (SIMEX; [19]). We intend to measure the

effect of GWAS sample overlap on estimates of shared disease associated gene counts

between pairs of traits using simulation because an analytic expression of it using the

definition of $c(t, t')$ is challenging to derive. In this procedure, we begin by estimating

posterior risk probabilities PRP_{kt} and $\text{PRP}_{kt'}$ for traits t and t' and all genes $k =$

$1, \ldots, |\mathcal{S}(t, t')|$ in the set of genes $\mathcal{S}(t, t')$ tested for association with both traits. We

require the estimated number of disease associated genes $c(t)$ and $c(t')$ for each trait,

their estimated SNP heritability or their τ^t and $\tau^{t'}$ values, and the estimated sample

overlap correlation parameter $v_{tt'}$ for the trait pair, which is estimable from GWAS

summary statistics as the empirical correlation between non-significant SNP-level Z-

statistics [32].

We then specify a grid of $v_{tt'}^*$ values in the interval $v_{tt'} < v_{tt'}^* \leq 1$, generate simulated

SNP-level summary statistics under the above model which includes GWAS sample

overlap, perform gene-based association testing using the sum of SNP chi-squares,

estimate gene-level posterior risk probabilities for each trait directly from the likelihoods

of the latent indicators (i.e., without integrating over the prior distributions of δ and τ),

and estimate the number of shared disease associated genes using the $c(t, t')$

estimator with $|\mathcal{S}(t, t')| = 8{,}148$ independent genes. We use the simulation-averaged

estimates of shared counts at each $v_{tt'}^*$ value to extrapolate from the observed shared

count $c(t, t')$ at $v_{tt'}$ back to the estimated shared count when there is no GWAS sample

overlap, denoted as $c(t, t; v_{tt'}^* = 0)$. We then multiply the original $c(t, t')$ estimate by

$c(t, t; v_{tt'}^* = 0)/c(t, t; v_{tt'}^* = v_{tt'})$ to adjust it for sample overlap.

Real data application

We estimated shared and non-shared disease associated gene counts using gene-

based test statistics (T_k) for 32 complex traits and statements of their null and non-null

distributions downloaded from a public database [20]. A full list of the repositories from

which these GWAS data were accessed is available in the **Appendix**, where the

phenotype label abbreviations and GWAS sample sizes are also present. All GWAS

were performed in populations of predominantly or exclusively European ancestry.

Genetic correlation estimates using LDSC are presented for all 496 trait pairs in

Supplementary Figure S11. Gene-based test statistics were calculated as the sum of

SNP-level association chi-square statistics from GWAS for all SNPs within ± 50 Kb of

the gene start and end base pair positions defined using Ensembl [73], and which could

be matched to the 1000 Genome Phase 3 European (1KGv3-EUR) LD reference panel

[74]. We defined Bonferroni significant trait-genes as those with a P-value less than

$0.05/d$, where d is the number of independent gene-based association test statistics

estimated using the method of [75] applied to each chromosome separately and

summed across them. Let $\mathbf{\Sigma}_c$ be the $R_c \times R_c$ matrix of correlations between gene-based

test statistics for a single trait calculated using the method described previously for the

cth chromosome and where $\lambda_{1c}, \ldots, \lambda_{R_c c}$ are its eigenvalues. We calculated d_c as

673
$$d_c = \sum_{i=1}^{R_c} I(\lambda_{ci} \geq 1) + \lambda_{ci} I(\lambda_{ci} < 1) \qquad (15)$$

where $I(a)$ is 1 if the argument a is true and 0 otherwise. Where any $\mathbf{\Sigma}_c$ matrix was not

positive definite, we used the nearest positive definite matrix via the transform of [76].

The number of independent gene-based association tests performed across the

genome was approximated as $d = \sum_c d_c$ which we found to be 12,272 using the 1KGv3-

EUR reference. LD scores and minor allele frequencies which parameterized the SNP-

level and subsequent gene-level models were calculated using the 1KGv3-EUR

reference panel. LD scores were calculated using SNPs in windows 1 centimorgan

wide.

To count the numbers of independent Bonferroni- and false discovery rate (FDR)-

significant genes in gene-based association testing as we show in **Figure 1a**, we first

formed the set $\{T_\ell\}$ such that $T_\ell > T_s \; \forall \; s \in \{s : s \neq \ell, \mathrm{Corr}(T_\ell, T_s) > \sqrt{0.5}\}$. The number of

independent significant genes was then the size of the set $\{T_\ell\}$ using either Bonferroni

or FDR correction. To identify drug target candidates, we joined lists of drug-target

interactions from ChEMBL [77], BindingDB [78], and GtoPdb [79] to their molecules

indicated in DrugBank [80], of which there were 3,369. We also estimated the risk-

directed genetic correlation between traits (*cf.* Equation 9), and all traits (see **Appendix**)

were inferred to already be coded in the direction of risk in their respective GWAS

except HDL, intelligence, and education.

Appendix

Here we present the names of each trait we studied, its abbreviation displayed

throughout the manuscript, the PubMed ID to the study from which the original GWAS

data came, and the GWAS sample size using the convention of <**abbreviation**: Full

name (PubMed ID; GWAS sample size)>. All GWAS cohorts were of strictly or

predominantly European ancestry.

- **AD**: Alzheimer's disease (35379992; 487,511)

- **ADHD**: Attention-deficit/hyperactivity disorder (36702997; 225,534)

- **AFIB**: Atrial fibrillation (36653681; 2,339,188)

- **agingR1**: R1 index of aging-associated brain atrophy (39147830; 49,482)

- **agingR2**: R2 index of aging-associated brain atrophy (39147830; 49,482)

- **agingR3**: R3 index of aging-associated brain atrophy (39147830; 49,482)

- **agingR4**: R4 index of aging-associated brain atrophy (39147830; 49,482)

- **agingR5**: R5 index of aging-associated brain atrophy (39147830; 49,482)

- **ALS**: Amyotrophic lateral sclerosis (34873335; 138,086)

- **BIP**: Bipolar I or II disorder (34002096; 413,466)

- **BMI**: Body mass index (30239722; 694,649)

- **CAD**: Coronary artery disease (36474045; 1,165,690)

- **CKD**: Chronic kidney disease (31152163; 625,219)

- **DBP**: Diastolic blood pressure (30224653; 757,601)

- **EDU**: Educational attainment (35361970; 3,037,499)

- **HDL**: High-density lipoprotein cholesterol (34887591; 1,320,016)

- **INT**: Fluid intelligence (36150907; 216,381)

- **LBD**: Lewy body dementia (33589841; 16,516)

- **LDL**: Low-density lipoprotein cholesterol (34887591; 1,320,016)

- **LUPUS**: Lupus (34278373; 324,698)

- **MDD**: Major depressive disorder (30718901; 807,553)

- **MS**: Multiple sclerosis (34737426; 456,348)

- **mvAGING**: Multivariate index of non-pathologic aging (37550455; 1,958,000)

- **PD**: Parkinson's disease (38155330; 611,485)

- **PP**: Pulse pressure (30224653; 757,601)

- **RA**: Rheumatoid arthritis (34737426; 456,348)

- **SBP**: Systolic blood pressure (30224653; 757,601)

- **SCZ**: Schizophrenia (35396580; 320,404)

- **SLEEP**: Sleep duration (30846698; 446,118)

- **STROKE**: Ischemic stroke (36180795; 1,296,908)

- **TG**: Triglycerides (34887591; 1,320,016)

- **T2D**: Type 2 diabetes (37034649; 1,528,967)

Software availability

We developed an R package to compute gene-level posterior risk probabilities and

estimates of shared polygenicity between traits which requires only gene- or SNP-level

summary statistics from GWAS and an LD reference panel (1000 Genomes Phase 3 is

provided) at https://github.com/noahlorinczcomi/bpact. All R code used to perform the

analyses presented in the main text is available at

https://github.com/noahlorinczcomi/bpact_analysis.

Data Availability

All data used in this study was downloaded from a public database of gene-based test

statistics for complex traits: https://nlorinczcomi.shinyapps.io/gent/. Linkage

disequilibrium reference panels were from the European population of 1000 Genomes

Phase 3 study [74] available at https://www.internationalgenome.org/ or

https://github.com/privefl/bigsnpr. We provide posterior risk probabilities for each of the

32 traits we studied and up to 17,166 genes and make the results available at

https://github.com/noahlorinczcomi/bpact. We also provide estimated total, shared, and

non-shared disease associated gene counts in the **Supplemental Data**.

Acknowledgements

Funding: This work was supported by the National Institute on Aging (NIA) under Award

Number R01AG084250, U01AG073323, R01AG066707, R01AG076448,

R01AG082118, RF1AG082211, R56AG074001, and R21AG083003, and the National

Institute of Neurological Disorders and Stroke (NINDS) under Award Number

RF1NS133812 to F.C. This work was partly supported by the Alzheimer's Association

award (ALZDISCOVERY-1051936) and the funds from the Alzheimer's Drug Discovery

Foundation (ADDF) to F.C.

Declaration of Interests

The authors declare no competing interests.

Figure legends

Figure 1

(a): Estimated counts of disease associated genes for 32 traits and their relationship

with the number of Bonferroni (left) and FDR (right) significant genes using gene-based

test statistics scaled by GWAS sample size. **(b)** Example of AD posterior risk

probabilities (PRPs) for all tested genes on chromosome 1. **(c)** Estimated counts of

disease associated genes on each chromosome from each of 32 traits calculated by

using the prior distributions of δ (the empirically derived prior proportion of non-disease

associated genes) for each trait. Different traits are represented by different colors

which are separated by horizontal lines in each vertical bar. **(d)** Example of shared

association on chromosome 7 for LDL and CAD. Probabilities in the 'CAD and LDL'

panel are the products of LDL- and CAD-specific posterior risk probabilities and

represent the posterior probability of shared association for each gene.

Figure 2

(a): Bars display estimated counts of all disease associated genes (light purple) and

non-shared disease associated genes (dark purple). Vertically oriented percentages

above each bar indicate the percentage of all disease associated genes that the

number of non-shared genes represent. **(b)** Cosine index values between all pairs of

traits (*cf.* Methods). Boxes are drawn around select sets of traits heuristically, and their

labels assigned manually. **(c)** Estimated proportions of all LBD-associated genes which

are shared with each other trait and their corresponding cosine and Jaccard index

values (*cf.* Methods). **(d)** Examples of two loci with evidence of shared association for

LBD and AD. 'LBD and AD' represents the posterior probability that each gene is

associated with both LBD and AD risk.

Figure 3

(a) Genome-wide plot of posterior risk probabilities (PRPs) for ALS (top) for each gene

and posterior probabilities that each gene is associated with ALS but not with any of the

other 31 studied traits (bottom). **(b)** (left) SNP-level association estimates from GWAS

for ALS, TG, and gene expression in the in the *KIT* locus (Chr4: 54524085-56606881).

(right) Bivariate SNP associations between ALS, TG, and thyroid eQTLs in the *KIT*

locus. Dark purple points are FDR significant at the 5% level for either trait on the x- or

y-axis. Lines are of best fit through sets of FDR-significant SNPs. **(c)** posterior risk

probabilities of three select genes for association with each of the 32 studied traits.

Vertical bars corresponding to ALS are colored in dark purple; bars not corresponding to

ALS are colored in light purple. **(d)** Bars display estimated counts of all druggable

disease associated genes (light purple) and non-shared druggable disease associated

genes (dark purple). Vertically oriented percentages above each bar indicate the

percentage of all druggable disease associated genes that the number of non-shared

druggable disease associated genes represent.

Figure 4

(a) Drug repurposing potential values (*cf.* Equation 9) for the 16 complex diseases we

studied and each tested druggable gene. Positive values denoted by purple bars are

candidate repurposable targets. **(b)** Examples of candidate repurposable drug targets

for AD with *PLEKHA1* (left) and ALS with *GAK* (right). Displayed are Z-statistics for

association at the SNP level from each respective GWAS for the indicated traits in the

$\pm$100Kb window around each gene body in hg19 coordinates. Dark purple points are

significant at P<5E-5 in an intersection union test for the pair of traits on the x- and y-

axes. Dark purple lines correspond to the best linear fit through these points. The null

region of the IUT at the 5E-5 level is indicated by the interior of joined vertical and

horizontal lines; the null region of a joint test at the 5E-5 level is indicated by the interior

of the circle centered at the origin. **(c)** Local SNP associations between *PLEKHA1*, AD,

and select tissue contexts of gene expression (left) and between *GAK*, ALS, and select

tissue contexts of gene expression (right). The color of each point represents its

squared LD with the lead SNP, which was estimated using the 1KGv3-EUR reference

panel (Siva et al., 2008). SNPs represented by triangles correspond to the SNPs which

are highlighted in dark purple in panel **(b)**.

Figure 1: Estimated disease associated gene counts and example inference

(a): Estimated counts of disease associated genes for 32 traits and their relationship

with the number of Bonferroni (left) and FDR (right) significant genes using gene-based

test statistics scaled by GWAS sample size. **(b)** Example of AD posterior risk

probabilities (PRPs) for all tested genes on chromosome 1. **(c)** Estimated counts of

disease associated genes on each chromosome from each of 32 traits calculated by

using the prior distributions of δ (the empirically derived prior proportion of non-disease

associated genes) for each trait. Different traits are represented by different colors

which are separated by horizontal lines in each vertical bar. **(d)** Example of shared

association on chromosome 7 for LDL and CAD. Probabilities in the 'CAD and LDL'

panel are the products of LDL- and CAD-specific posterior risk probabilities and

represent the posterior probability of shared association for each gene.

Figure 2: Measuring shared polygenicity across traits

(a): Bars display estimated counts of all disease associated genes (light purple) and

non-shared disease associated genes (dark purple). Vertically oriented percentages

above each bar indicate the percentage of all disease associated genes that the

number of non-shared genes represent. **(b)** Cosine index values between all pairs of

traits (*cf.* Methods). Boxes are drawn around select sets of traits heuristically, and their

849   labels assigned manually. **(c)** Estimated proportions of all LBD-associated genes which

850   are shared with each other trait and their corresponding cosine and Jaccard index

851   values (*cf.* Methods). **(d)** Examples of two loci with evidence of shared association for

852   LBD and AD. 'LBD and AD' represents the posterior probability that each gene is

853   associated with both LBD and AD risk.

Figure 3: Shared association of ALS druggable genes with other traits

a) ALS marginal and non-shared posterior probabilities for druggable genes

b) SNP associations with three traits in *KIT* locus

c) Shared/non-shared druggable ALS genes
d) Associated druggable gene counts

(a) Genome-wide plot of posterior risk probabilities (PRPs) for ALS (top) for each gene

and posterior probabilities that each gene is associated with ALS but not with any of the

other 31 studied traits (bottom). **(b)** (left) SNP-level association estimates from GWAS

for ALS, TG, and gene expression in the in the *KIT* locus (Chr4: 54524085-56606881).

(right) Bivariate SNP associations between ALS, TG, and thyroid eQTLs in the *KIT*

locus. Dark purple points are FDR significant at the 5% level for either trait on the x- or

y-axis. Lines are of best fit through sets of FDR-significant SNPs. **(c)** posterior risk

probabilities of three select genes for association with each of the 32 studied traits.

Vertical bars corresponding to ALS are colored in dark purple; bars not corresponding to

ALS are colored in light purple. **(d)** Bars display estimated counts of all druggable

disease associated genes (light purple) and non-shared druggable disease associated

genes (dark purple). Vertically oriented percentages above each bar indicate the

percentage of all druggable disease associated genes that the number of non-shared

druggable disease associated genes represent.

Figure 4: Drug repurposing targets for disease traits

a) Genome-wide drug repurposing potential for complex diseases

b) SNP-level associations between AD, ALS, and their pleiotropic genes

c) Shared local GWAS and eQTL signals for *PLEKHA1* and *GAK*

(a) Drug repurposing potential values (*cf.* Equation 9) for the 16 complex diseases we

studied and each tested druggable gene. Positive values denoted by purple bars are

candidate repurposable targets. **(b)** Examples of candidate repurposable drug targets

for AD with *PLEKHA1* (left) and ALS with *GAK* (right). Displayed are Z-statistics for

association at the SNP level from each respective GWAS for the indicated traits in the

$\pm$100Kb window around each gene body in hg19 coordinates. Dark purple points are

significant at P<5E-5 in an intersection union test for the pair of traits on the x- and y-

axes. Dark purple lines correspond to the best linear fit through these points. The null

region of the IUT at the 5E-5 level is indicated by the interior of joined vertical and

horizontal lines; the null region of a joint test at the 5E-5 level is indicated by the interior

of the circle centered at the origin. **(c)** Local SNP associations between *PLEKHA1*, AD,

and select tissue contexts of gene expression (left) and between *GAK*, ALS, and select

tissue contexts of gene expression (right). The color of each point represents its

squared LD with the lead SNP, which was estimated using the 1KGv3-EUR reference

panel (Siva et al., 2008). SNPs represented by triangles correspond to the SNPs which

are highlighted in dark purple in panel **(b)**.

References

1. Visscher, P.M., et al., *Discovery and implications of polygenicity of common diseases.* Science, 2021. **373**(6562): p. 1468–1473.
2. Jiang, X., et al., *Shared heritability and functional enrichment across six solid cancers.* Nature communications, 2019. **10**(1): p. 431.
3. Ballard, J.L. and L.J. O'Connor, *Shared components of heritability across genetically correlated traits.* The American Journal of Human Genetics, 2022. **109**(6): p. 989–1006.
4. Lounkine, E., et al., *Large-scale prediction and testing of drug activity on side-effect targets.* Nature, 2012. **486**(7403): p. 361–367.
5. Bedi, O., et al., *Pleiotropic effects of statins: new therapeutic targets in drug design.* Naunyn-Schmiedeberg's archives of pharmacology, 2016. **389**: p. 695–712.
6. Nguyen, P.A., et al., *Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects.* Nature communications, 2019. **10**(1): p. 1579.
7. Woodward, D.J., et al., *Leveraging pleiotropy for the improved treatment of psychiatric disorders.* Molecular Psychiatry, 2024: p. 1–17.
8. Mao, T., et al., *Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis.* Diabetology & Metabolic Syndrome, 2024. **16**(1): p. 208.
9. Horton, J.D., J.C. Cohen, and H.H. Hobbs, *Molecular biology of PCSK9: its role in LDL metabolism.* Trends in biochemical sciences, 2007. **32**(2): p. 71–77.
10. Cohen, J.C.B., E.; Mosley Jr, T. H.; Hobbs, H. H., *Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.* New England Journal of Medicine, 2006. **354**(12): p. 1264–1272.
11. Leeuw, C.A., et al., *MAGMA: generalized gene-set analysis of GWAS data.* PLoS computational biology, 2015. **11**(4): p. 1004219.
12. Sivakumaran, S., et al., *Abundant pleiotropy in human complex diseases and traits.* The American Journal of Human Genetics, 2011. **89**(5): p. 607–618.
13. Bulik-Sullivan, B.K., et al., *Schizophrenia Working Group of the Psychiatric Genomics Consortium.* Nature genetics, 2015. **47**(3): p. 291–295.
14. Wu, T., et al., *Polygenic power calculator: Statistical power and polygenic prediction accuracy of genome-wide association studies of complex traits.* Frontiers in Genetics, 2022. **13**: p. 989639.
15. Schaid, D.J., et al., *Statistical methods for testing genetic pleiotropy.* Genetics, 2016. **204**(2): p. 483–497.
16. Frei, O.H., D.; Smeland, O.B.; Shadrin, A.A.; Fan, C.C.; Maeland, S.; O'Connell, K.S.; Wang, Y.; Djurovic, S.; Thompson, W.K.; Andreassen, O.A.;, *Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation.* Nature communications, 2019. **10**(1).
17. Parker, N.C., W.; Hindley, G.F.; O'Connell, K.S.; Parekh, P.; Hagen, E.; Smeland, O.B.; Djurovic, S.; Shadrin, A.A.; Andreassen, O.A.; Frei, O., *Sourcing Bivariate Genetic Overlap for Polygenic Prediction using MiXeR-Pred.* medrXiv, 2024.

18. Akdeniz, B.C.F., O.; Shadrin, A.; Vetrov, D.; Kropotov, D.; Hovig, E.; Andreassen,
O.A.; Dale, A.M., *Finemap-MiXeR: A variational Bayesian approach for genetic*
finemapping. PLoS Genetics, 2024. **20**(8).

19. Stefanski, L.A. and J.R. Cook, *Simulation-extrapolation: the measurement error*
jackknife. Journal of the American Statistical Association, 1995. **90**(432): p.
1247–1256.

20. Lorincz-Comi, N.S., W.; Chen, X.; Rivera Paz, I.; Hou, Y.; Zhou, Y.; Xu, J.;
William, M.; Barnard, J.; Pieper, A.; Haines, J.; Chung, M.; Cheng, F., *Combining*
xQTL and Genome-Wide Association Studies from Ethnically Diverse
Populations Improves Druggable Gene Discovery. SRN, 2025.

21. Sachse, S.M., et al., *Nuclear import of the DSCAM-cytoplasmic domain drives*
signaling capable of inhibiting synapse formation. The EMBO journal, 2019.
38(6): p. 99669.

22. Chen, X., et al., *The study of Alzheimer's disease risk diagnosis based on natural*
killer cell marker genes in the multi-omics data. Journal of Alzheimer's Disease,
2024. **0**(0).

23. Ballantyne, C.M., *Low-density lipoproteins and risk for coronary artery disease.*
The American journal of cardiology, 1998. **82**(8): p. 3–12.

24. Xie, J., et al., *The unsupervised feature selection algorithms based on standard*
deviation and cosine similarity for genomic data analysis. Frontiers in Genetics,
2021. **12**: p. 684100.

25. Frech, C. and N. Chen, *Genome-wide comparative gene family classification.*
PLoS one, 2010. **5**(10): p. 13409.

26. Rosoff, D.B., et al., *Multivariate genome-wide analysis of aging-related traits*
identifies novel loci and new drug targets for healthy aging. Nature aging, 2023.
3(8): p. 1020–1035.

27. Qiang, Y.X., et al., *Associations of blood cell indices and anemia with risk of*
incident dementia: A prospective cohort study of 313,448 participants.
Alzheimer's & Dementia, 2023. **19**(9): p. 3965–3976.

28. Arbogast, T., et al., *Kctd13-deficient mice display short-term memory impairment*
and sex-dependent genetic interactions. Human molecular genetics, 2019. **28**(9):
p. 1474–1486.

29. Jadiya, P., et al., *Impaired mitochondrial calcium efflux contributes to disease*
progression in models of Alzheimer's disease. Nature communications, 2019.
10(1): p. 3885.

30. Jadiya, P., et al., *Genetic Rescue of Mitochondrial Calcium Efflux in Alzheimer's*
Disease Preserves Mitochondrial Function and Protects against Neuronal Cell
Death. Biophysical Journal, 2017. **112**(3): p. 445.

31. Lonsdale, J., et al., *The genotype-tissue expression (GTEx) project.* Nature
genetics, 2013. **45**(6): p. 580–585.

32. Lorincz-Comi, N., et al., *MRBEE: A bias-corrected multivariable Mendelian*
randomization method. Human Genetics and Genomics Advances, 2024. **5**(3).

33. Mattiola, I., A. Mantovani, and M. Locati, *The tetraspan MS4A family in*
homeostasis, immunity, and disease. Trends in Immunology, 2021. **42**(9): p. 764–
781.

34. Luo, X., et al., *MS4A superfamily molecules in tumors, Alzheimer's and autoimmune diseases.* Frontiers in Immunology, 2024. **15**: p. 1481494.
35. Ma, J., J.T. Yu, and L. Tan, *MS4A cluster in Alzheimer's disease.* Molecular neurobiology, 2015. **51**: p. 1240–1248.
36. Deming, Y., et al., *The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.* Science translational medicine, 2019. **11**(505): p. 2291.
37. Falgarone, G. and G. Chiocchia, *Clusterin: A multifacet protein at the crossroad of inflammation and autoimmunity.* Advances in cancer research, 2009. **104**: p. 139–170.
38. Sardi, F., et al., *Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.* Autoimmunity reviews, 2011. **11**(2): p. 149–153.
39. Bergink, V., S.M. Gibney, and H.A. Drexhage, *Autoimmunity, inflammation, and psychosis: a search for peripheral markers.* Biological psychiatry, 2014. **75**(4): p. 324–331.
40. Jong, M.C., M.H. Hofker, and L.M. Havekes, *Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3.* Arteriosclerosis, thrombosis, and vascular biology, 1999. **19**(3): p. 472–484.
41. Gao, M., et al., *ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death.* Metabolism, 2020. **109**: p. 154296.
42. Knox, C., et al., *DrugBank 6.0: the DrugBank knowledgebase for 2024.* Nucleic acids research, 2024. **52**(D1): p. 1265– 1275.
43. Tomar, M., et al., *A clinical and computational study on anti-obesity effects of hydroxycitric acid.* RSC advances, 2019. **9**(32): p. 18578–18588.
44. Yadikar, N., et al., *Exploring the mechanism of citric acid for treating glucose metabolism disorder induced by hyperlipidemia.* Journal of Food Biochemistry, 2022. **46**(12): p. 14404.
45. Amin, K.A., H.H. Kamel, and M.A. Abd Eltawab, *The relation of high fat diet, metabolic disturbances and brain oxidative dysfunction: modulation by hydroxy citric acid.* Lipids in health and disease, 2011. **10**: p. 1–11.
46. Abdel-Salam, O.M.E., et al., *Citric acid effects on brain and liver oxidative stress in lipopolysaccharide-treated mice.* Journal of medicinal food, 2014. **17**(5).
47. Suner, S.S., et al., *Versatile fluorescent carbon dots from citric acid and cysteine with antimicrobial, anti-biofilm, antioxidant, and AChE enzyme inhibition capabilities.* Journal of fluorescence, 2021. **31**(6): p. 1705–1717.
48. Marucci, G., et al., *Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.* Neuropharmacology, 2021. **190**: p. 108352.
49. Cerbai, F., et al., *N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.* European journal of pharmacology, 2007. **572**(2-3): p. 142–150.
50. Furukawa-Hibi, Y., et al., *Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.* Behavioural brain research, 2011. **225**(1): p. 222–229.
51. Markham, A., *Fostamatinib: first global approval.* Drugs, 2018. **78**: p. 959–963.

52.   Yergolkar, A.V., et al., *PND24 target identification and drug repurposing for*
Parkinson's disease: A novel integrative computational approach. Value in Health
Regional Issues, 2020. **22**: p. 79.
53.   Duan, Q.Q., et al., *TBK1, a prioritized drug repurposing target for amyotrophic*
lateral sclerosis: evidence from druggable genome Mendelian randomization and
pharmacological verification in vitro. BMC medicine, 2024. **22**(1): p. 96.
54.   Eshak, D. and M. Arumugam, *Unveiling therapeutic biomarkers and druggable*
targets in ALS: An integrative microarray analysis, molecular docking, and
structural dynamic studies. Computational Biology and Chemistry, 2024. **113**: p.
108211.
55.   Birkle, T.J. and G.C. Brown, *Syk inhibitors protect against microglia-mediated*
neuronal loss in culture. Frontiers in Aging Neuroscience, 2023. **15**: p. 1120952.
56.   Zhou, C., et al., *Activation of spleen tyrosine kinase (SYK) contributes to*
neuronal pyroptosis and cognitive impairment in diabetic mice via the
NLRP3/Caspase-1/GSDMD signaling pathway. Experimental Gerontology, 2024.
198: p. 112626.
57.   Miyazaki, M., et al., *Targeted disruption of GAK stagnates autophagic flux by*
disturbing lysosomal dynamics. International Journal of Molecular Medicine,
2021. **48**(4): p. 1–18.
58.   Pan, J., et al., *A kinome-wide siRNA screen identifies multiple roles for protein*
kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in
protection against apoptosis in VHL−/− renal carcinoma cells, despite activation
of the NF-κB pathway. Journal of biomolecular screening, 2013. **18**(7): p. 782–
796.
59.   Liu, T., et al., *NF-κB signaling in inflammation.* Signal transduction and targeted
therapy, 2017. **2**(1): p. 1–9.
60.   Shi, J.H., X. Xie, and S.C. Sun, *TBK1 as a regulator of autoimmunity and*
antitumor immunity. Cellular & molecular immunology, 2018. **15**(8): p. 743–745.
61.   Balka, K.R., et al., *TBK1 and IKKε act redundantly to mediate STING-induced*
NF-κB responses in myeloid cells. Cell reports, 2020. **31**(1).
62.   Qian, Y., et al., *The sodium channel subunit SCNN1B suppresses colorectal*
cancer via suppression of active c-Raf and MAPK signaling cascade. Oncogene,
2023. **42**(8): p. 601–612.
63.   Sahana, T.G. and K. Zhang, *Mitogen-activated protein kinase pathway in*
amyotrophic lateral sclerosis. Biomedicines, 2021. **9**(8): p. 969.
64.   Yadav, R.K., E. Minz, and S. Mehan, *Understanding abnormal c-JNK/p38MAPK*
signaling in amyotrophic lateral sclerosis: potential drug targets and influences on
neurological disorders. CNS & Neurological Disorders-Drug Targets (Formerly
Current Drug Targets-CNS & Neurological Disorders, 2021. **20**(5): p. 417–429.
65.   Lemmon, M.A., *Pleckstrin homology (PH) domains and phosphoinositides*, in
Biochemical Society Symposia. 2007, Portland Press Ltd. p. 81–93.
66.   Bellenguez, C.K., F.; Jansen, I.E.; Kleineidam, L.; Moreno-Grau, S.; Amin, N.;
Naj, A.C.; Campos-Martin, R.; Grenier-Boley, B.; Andrade, V.; Holmans, P.A.,
New insights into the genetic etiology of Alzheimer's disease and related
dementias. Nature genetics, 2022. **54**(4): p. 412-436.

67.   Loos, R.J. and G.S. Yeo, *The genetics of obesity: from discovery to biology.*
1073   Nature Reviews Genetics, 2022. **23**(2): p. 120–133.
1074   68.   Wu, T. and P.C. Sham, *On the transformation of genetic effect size from logit to*
1075   *liability scale.* Behavior Genetics, 2021. **51**(3): p. 215–222.
1076   69.   Zhu, X. and M. Stephens, *Bayesian large-scale multiple regression with*
1077   *summary statistics from genome-wide association studies.* The annals of applied
1078   statistics, 2017. **11**(3): p. 1561.
1079   70.   Privé, F., *Optimal linkage disequilibrium splitting.* Bioinformatics, 2022. **38**(1): p.
1080   255–256.
1081   71.   Rubin, D.B., *Multiple imputation after 18+ years.* Journal of the American
1082   statistical Association, 1996. **91**(434): p. 473–489.
1083   72.   LeBlanc, M., et al., *Schizophrenia and Bipolar Disorder Working Groups of the*
1084   *Psychiatric Genomics Consortium.* BMC genomics, 2018. **19**: p. 1–15.
1085   73.   Harrison, P.W., et al., *Ensembl 2024.* Nucleic acids research, 2024. **52**(D1): p.
1086   891– 899.
1087   74.   Siva, N., *1000 Genomes project.* Nature biotechnology, 2008. **26**(3): p. 256–257.
1088   75.   Jiang, L., et al., *Powerful and robust inference of complex phenotypes' causal*
1089   *genes with dependent expression quantitative loci by a median-based Mendelian*
1090   *randomization.* The American Journal of Human Genetics, 2022. **109**(5): p. 838–
1091   856.
1092   76.   Choi, Y.G., et al., *Fixed support positive-definite modification of covariance matrix*
1093   *estimators via linear shrinkage.* Journal of Multivariate Analysis, 2019. **171**: p.
1094   234–249.
1095   77.   Gaulton, A., et al., *ChEMBL: a large-scale bioactivity database for drug discovery.*
1096   Nucleic acids research, 2012. **40**(D1): p. 1100– 1107.
1097   78.   Liu, T., et al., *BindingDB in 2024: a FAIR knowledgebase of protein-small*
1098   *molecule binding data.* Nucleic Acids Research, 2024. **gkae1075**.
1099   79.   Harding, S.D., et al., *The IUPHAR/BPS guide to PHARMACOLOGY in 2022:*
1100   *curating pharmacology for COVID-19, malaria and antibacterials.* Nucleic Acids
1101   Research, 2022. **50**(D1): p. 1282– 1294.
1102   80.   Wishart, D.S., et al., *DrugBank 5.0: a major update to the DrugBank database for*
1103   *2018.* Nucleic acids research, 2018. **46**(D1): p. 1074– 1082.
1104